Table 1.
Characteristics | Viral Suppression (N=136) |
Viral Failure (N=91) |
pa | ||
---|---|---|---|---|---|
No. | % | No. | % | ||
| |||||
Hospital Site | |||||
| |||||
Kilimanjaro Christian Medical Centre | 81 | 59.6 | 58 | 63.7 | 0.527 |
Mawenzi Hospital | 55 | 40.4 | 33 | 36.3 | |
| |||||
Age, y | |||||
| |||||
Median (IQR) | 16 | (14–18) | 16 | (14–18) | 0.679 |
| |||||
Gender | |||||
| |||||
Female | 66 | 48.5 | 36 | 39.6 | 0.183 |
Male | 70 | 51.5 | 55 | 60.4 | |
| |||||
Time receiving ART, y | |||||
| |||||
Median (IQR) | 6 | (4–9) | 6 | (4–8) | 0.381 |
| |||||
Current ART | |||||
| |||||
NNRTI-based | 103 | 75.7 | 61 | 67.0 | 0.151 |
PI-based | 33 | 24.3 | 30 | 33.0 | |
| |||||
CD4, cells/mm3 | |||||
| |||||
< 350 | 28 | 20.6 | 41 | 45.1 | < 0.001 |
>/= 350 | 108 | 79.4 | 50 | 54.9 | |
| |||||
Self-Reported Adherent | |||||
| |||||
Adherent | 95 | 69.9 | 60 | 65.9 | 0.534 |
Non-Adherent | 41 | 30.1 | 31 | 34.1 |
Viral Failure: HIV-1 RNA >400 copies/mL; IQR, interquartile range; ART, antiretroviral therapy; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor;
Chi-Square test of independence or Wilcoxon rank sum test.